Partial Response
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (NCT01844986) | AstraZeneca | 2013-08-26 |
Track Partial Response automatically
Every clearance here is in the API, with alerts when new ones post.